Ambrisentan
- Generic Name
- Ambrisentan
- Brand Names
- Letairis, Volibris, Ambrisentan Mylan
- Drug Type
- Small Molecule
- Chemical Formula
- C22H22N2O4
- CAS Number
- 177036-94-1
- Unique Ingredient Identifier
- HW6NV07QEC
- Background
Ambrisentan is an orally active selective type A endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension. It is approved in Europe, Canada and the United States for use as a single agent to improve exercise ability and delay clinical worsening. In addition, it is approved in the United States for use in combination with ...
- Indication
用于治疗肺动脉高血压(PAH)。
- Associated Conditions
- Pulmonary arterial hypertension WHO functional class I
- Associated Therapies
- -
Phase 2 Extension Study of Ambrisentan in Pulmonary Arterial Hypertension
- Conditions
- First Posted Date
- 2007-01-18
- Last Posted Date
- 2012-01-27
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 54
- Registration Number
- NCT00424021
Safety and Efficacy Study of Ambrisentan in Subjects With Pulmonary Hypertension
- First Posted Date
- 2006-09-25
- Last Posted Date
- 2012-04-05
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 224
- Registration Number
- NCT00380068
- Locations
- 🇺🇸
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, California, United States
🇺🇸University of Chicago Hospitals, Chicago, Illinois, United States
🇺🇸Johns Hopkins University, Baltimore, Maryland, United States
ARIES - Ambrisentan in Patients With Moderate to Severe Pulmonary Arterial Hypertension (PAH)
- Conditions
- First Posted Date
- 2004-09-14
- Last Posted Date
- 2010-03-08
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 372
- Registration Number
- NCT00091598
- Locations
- 🇺🇸
University of Pennsylvania Hospital, Philadelphia, Pennsylvania, United States
🇺🇸Brentwood Biomedical Research Institute, Los Angeles, California, United States
🇺🇸Medical College of Georgia, Augusta, Georgia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.